

CURRICULUM VITAE

Peter Lucas Havens, M.D., M.S.
April, 2020

OFFICE ADDRESS: Pediatric Infectious Diseases, Suite C450
Children's Wisconsin
P.O. Box 1997
Milwaukee, WI 53201-1997
Phone: 414-337-7070

EDUCATION:

1975 A.B., Cum Laude, Harvard College, Cambridge, Massachusetts
1980 M.D., University of Missouri, School of Medicine, Kansas City, Missouri
1987 S.M., Harvard School of Public Health, Department of Epidemiology, Boston, Massachusetts

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1981 Intern, Internal Medicine, Truman Medical Center, Kansas City, Missouri
1981-1984 Intern, Junior Assistant Resident and Senior Assistant Resident in Pediatrics, The Children's Hospital, Boston, Massachusetts
1981-1987 Clinical Fellow, Pediatrics, Harvard Medical School, Boston, Massachusetts
1984-1987 Fellow, Pediatric Infectious Diseases, The Children's Hospital, Boston, Massachusetts
1985-1987 Fellow, Anesthesia (Intensive Care), The Children's Hospital, Boston, Massachusetts

FACULTY APPOINTMENTS (Including Secondary Appointments):

1987-1991 Assistant Professor, Pediatrics, Divisions of Critical Care and Infectious Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin
1991 Assistant Professor, Biostatistics/Clinical Epidemiology, Medical College of Wisconsin, Milwaukee, Wisconsin
1991-1997 Associate Professor, Pediatrics and Epidemiology, Divisions of Critical Care and Infectious Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin
1997-present Professor, Pediatrics and Population Health (before 2006 = Epidemiology), Medical College of Wisconsin, Milwaukee, WI (with tenure, July, 2000)

HOSPITAL AND ADMINISTRATIVE APPOINTMENTS:

1987-2000 Associate Director, Pediatric Intensive Care Unit, Children's Hospital of Wisconsin, Milwaukee, Wisconsin
1987-Present Consultant in Pediatric Infectious Diseases, Children's Hospital of Wisconsin, Milwaukee, WI
1988-1995 Director, Fellowship in Pediatric Critical Care Medicine, Children's Hospital of Wisconsin/Medical College, Wisconsin, Milwaukee, Wisconsin
1990-2014 Infectious Diseases Consultant, Heart Transplantation Program, Children's Hospital of Wisconsin, Milwaukee, Wisconsin
1991-Present Director, Pediatric HIV Care Program, Children's Hospital of Wisconsin, Milwaukee, Wisconsin

- 1995-1997 Director, Research Education, Fellowship in Pediatric Critical Care Medicine, Children's Hospital of Wisconsin/Medical College, Wisconsin, Milwaukee, Wisconsin
- 1997-1998 Co-Director, Research Education, Fellowship in Pediatric Critical Care Medicine, Children's Hospital of Wisconsin/Medical College of Wisconsin, Milwaukee, Wisconsin
- 2006-2011 Executive Committee, Department of Pediatrics
- 2011-2013 Interim Vice-Chair, Department of Pediatrics
- 2013-2020 Vice-Chair, Department of Pediatrics

HOSPITAL STAFF PRIVILEGES:

1987-present Children’s Hospital of Wisconsin, 9000 W. Wisconsin Avenue, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATIONS:

- 1987 American Board of Pediatrics, Certification in General Pediatrics
- 1987 American Board of Pediatrics, sub-specialty certification in Pediatric Critical Care
- 1995 American Board of Pediatrics, sub-specialty certification in Pediatric Infectious Diseases
- 1995 American Board of Pediatrics, re-certification in Pediatric Critical Care
- 2001 American Board of Pediatrics, re-certification in Pediatric Critical Care
- 2001 American Board of Pediatrics, re-certification in Pediatric Infectious Diseases
- 2008 American Board of Pediatrics, re-certification in Pediatric Infectious Diseases

<u>Licensure:</u>	<u>Number</u>
Massachusetts (inactive)	
Wisconsin	28368

AWARDS, HONORS:

- 1970 National Merit Scholarship
- 1975 Honors in Biology, Harvard University
- 1981 Upjohn Award, University of Missouri, Kansas City, School of Medicine
- 1988 Most Outstanding Teacher Award, Pediatric House Staff, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
- 1989 Most Outstanding Teacher Award, Pediatric House Staff, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
- 1991 Honor Roll of Outstanding Teachers, Pediatric House Staff, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
- 1993 Wisconsin Maternal and Child Health Coalition Achievement Award: "Outstanding Sustained Public Information Program", along with all members of the Pediatric HIV Coordinating Committee of Milwaukee
- 1993 Edward J. Lennon Endowed Clinical Teaching Award, Medical College of Wisconsin, Milwaukee, Wisconsin
- 1994 A.H. Robins / Wyeth-Ayerst Laboratories Miracle Maker Award for excellence in patient care, service to the community, and health education.
- 1995 E. Grey Dimond, M.D. Take Wing Award, for "...exceptional professional or personal accomplishments that contribute to the field of medicine..." University of Missouri-

- Kansas City School of Medicine, Kansas City, MO.
- 1995 Teaching Excellence Award, Pediatric House Staff, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
 - 1997 Award for Innovation, Association for Care of Children's Health (ACCH), honorable mention, with other members of the Wisconsin HIV Primary Care Support Network
 - 1997 Medical College of Wisconsin Society of Teaching Scholars
 - 2000-present Milwaukee Magazine: One of the Best Physicians in Milwaukee
 - 2002-present Included in "Best Doctors in America"
 - 2002 Wisconsin Chapter, American Academy of Pediatrics "2002 Pediatrician of the Year"
 - 2005 AIDS Resource Center of Wisconsin "Twenty Giving Twenty" award, for service to children and families with HIV in Wisconsin.
 - 2005 "Clinician's Clinician," for clinical excellence, voted by the faculty of the Department of Pediatrics, Medical college of Wisconsin
 - 2005 Most Outstanding Teacher Award, Pediatric House Staff, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
 - 2007 AIDS Resource Center of Wisconsin award for leadership, for role in programs for prevention of mother to child transmission of HIV in Wisconsin
 - 2007 Presidential Volunteer Award, US Agency for International Development (USAID) for work in the Pediatric ART Centers of Excellence, Lusaka and Livingstone, Zambia
 - 2009 Most Outstanding Teacher Award, Pediatric House Staff, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
 - 2013 Most Outstanding Teacher of the Full Time Faculty, Pediatric House Staff, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
 - 2016, '17, '18, '19 Expert Teacher award (top 10% of teachers by peer, community provider, and learner survey), Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI
 - 2016, '17, '18, '19 Expert Clinician award (top 10% of clinicians by peer survey), Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI
 - 2017 Standing Ovation Award, Children's Hospital of Wisconsin, for work on the team leading to the Children's Hospital of Wisconsin HIV Post Exposure Plan for victims of sexual assault cared for in the Emergency Department.
 - 2018 High 5 award as one of the top 5 teachers of Department of Pediatrics Residents
 - 2019 Master Teacher Award (given for multiple years as an Expert Teacher), Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI
 - 2019 Master Clinician Award (given for multiple years as an Expert Clinician), Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI

MEMBERSHIPS IN PROFESSIONAL AND HONORARY SOCIETIES:

- 1986 Society of Critical Care Medicine
- 1987 Fellow, American Academy of Pediatrics
- 1987 American Society for Microbiology
- 1988 Pediatric Infectious Disease Society
- 1991 Infectious Diseases Society of America
- 1994 Society for Epidemiologic Research

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Journal Review

Pediatric Research
Clinical Pediatrics
Western Journal of Medicine
Journal of Intensive Care Medicine
Journal of the American Medical Association
Clinical Infectious Diseases
Pediatric Dermatology
Consultant
Journal of Pediatrics
Pediatrics
Pediatric Infectious Diseases Journal
New England Journal of Medicine
JAIDS
Journal of the Pediatric Infectious Diseases Society
JAMA Pediatrics
American Journal of Tropical Medicine and Hygiene
Lancet HIV
Antiviral Therapy
Advances in Pharmacological Sciences

INTERNATIONAL ADVISORY COMMITTEES AND/OR ACTIVITIES

2005 Consultant, Center for International Health Pediatric HIV Training Program, Kenya
2006 Consultant, Center for International Health Pediatric HIV Pharmacy Training Program, Zambia
2007 Lecturer for Centers for Disease Control (CDC) Training conference in Pediatric and Perinatal HIV, St. Petersburg, Russia, March 18-23, 2007
2007-8 Consultant, Roche Pharmaceuticals, Nelfinavir-EMS contamination June 2007 and June 2008
2007-2010 Consultant and lecturer, Center for International Health Pediatric HIV Pharmacy Training Program, Lusaka and Livingstone, Zambia
2011 Consultant, "Tenofovir use in children and Adolescents, World Health Organization, Pediatric Antiretroviral Working Group, Geneva, Switzerland.
2012 18th International AIDS Conference abstract reviewer
2014 20th International AIDS Conference abstract reviewer
2014 Clinton Health Access Initiative (CHAI) Tenofovir disoproxil fumarate (xb) Program, Clinical Advisory Board, Member
2015, '16, '18 International AIDS Society Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) grants reviewer

NATIONAL ADVISORY COMMITTEES AND/OR ACTIVITIES

1991-1995 Executive Committee, Pediatric Critical Care Study Group
1992-1998 Chairman, Data Safety Monitoring Board, Randomized Trial of Early Dexamethasone versus Placebo for Prevention of Chronic Lung Disease in Neonates,

- Perinatal Foundation, Milwaukee, WI.
- 1994-1995 Chairman, Protocol Review Committee, Pediatric Critical Care Study Group.
- 1994 Program Committee, Maternal and Child Health Bureau Meeting on HIV/AIDS Primary Care for Children and Families, Boston, MA.
- 1994 Grants reviewer for Ryan White Title IV Planning and Initial Development Projects, Maternal and Child Health Bureau, Hemophilia and AIDS Program Branch, Rockville, MD
- 1994 Scientific Committee, Seventh Pediatric Critical Care Colloquium, Seattle, WA
- 1994 1994-95 Society of Critical Care Medicine Awards Committee
- 1995 Outcome Evaluation Workgroup, Ryan White Title IV Program, Maternal and Child Health Bureau, Rockville, MD
- 1996-1997 Chair, Data Safety/Monitoring Board, Partial Liquid Ventilation Pediatric Multicenter Study, Alliance Pharmaceuticals, San Diego, CA
- 1996-1997 Member, Working Group on Antiretroviral Therapy and Medical Management of Children with HIV Infection, National Pediatric and Family HIV Resource Center, Newark, NJ
- 1996-1998 Member, Data Safety/Monitoring Board, Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease, Vermont-Oxford Neonatal Network
- 1996 Consulting Faculty, University of Rhode Island Pharmacy Practitioner Education Program
- 1996 Member, Special Review Committee for Pediatric AIDS Clinical Trials Group RFA AI-96-001, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Washington, D.C.
- 1996 Member, Ryan White Title IV Annual Meeting Planning Committee, Maternal and Child Health Bureau, Hemophilia and AIDS Program Branch, Rockville, MD
- 1997 Member, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Special Emphasis Panel for PA-AI-DAIDS-96-004, Women and Infants Transmission Study.
- 1997 Member, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Special Emphasis Panel for RFP NIH-NIAID-DAIDS-98-05, Statistical and Clinical Coordinating Center for the Women and Infants Transmission Study.
- 1997-2001 Member, Executive Committee and Board of Trustees, HIV Quality Care Network of the Infectious Diseases Society of America
- 1999-2008 Committee on Pediatric AIDS, American Academy of Pediatrics (AAP COPA).
 Member, 1999-2008
 Chair, July 2004 to June 2008.
- 2000 Chair, Interim Study Monitoring Committee, Pediatric AIDS Clinical Trials Group Study 247
- 2000-present Department of Health and Human Services (DHHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children—A Working Group of the Office of AIDS Research Advisory Council (OARAC)
 Member from 2000
 Co-Chair, 2003 to 2006
 Co-Chair, 2006 (December) to 2016.
 Chair, 2016 (Jan) to 2020
- 2001-2002 Chair, Study Monitoring Committee, Pediatric AIDS Clinical Trials Group Study 247
- 2001-2003 Invited Lecturer and Consultant, CDC Smallpox Preparedness and Response Training
- 2002-2016 Member, Therapeutic Leadership Group of the Adolescent Medicine Leadership

- 2005 Group of the Adolescent Medicine Trials Network for HIV/AIDS Intervention Centers for Disease Control and Prevention Consultation on Pediatric HIV Case Definition, Rapporteur
- 2006-2009 Antiviral Drugs Advisory Committee, Food and Drug Administration, Rockville, MD
- 2007 Reviewer, NICHD Pediatric and Perinatal HIV Studies Network site proposals, Rockville, MD.
- 2008 Centers for Disease Control and Prevention Consultation on Prevention of Mother to Child Transmission of HIV in the United States, Participant, April 1-3, 2008.
- 2010-2011 Centers for Disease Control Elimination of Mother-to-Child HIV Transmission in the United States National Stakeholders' Research Working group
- 2011 Centers for Disease Control Pediatric HIV Case Definition Revision working Group
- 2012 National Quality Forum 2012 Infectious Diseases Endorsement Maintenance Project Steering Committee (nominated by Health Resources and Services Administration)
- 2013 NIAID/NIH RFA AI-12-018: Clinical Trial Unit for NIAID Networks. Peer Review Panel Member
- 2014 NICHD/NIH 2015/01 ZRG1 AARR-F (45) Program Project: AIDS and AIDS Related Research. Peer Review Panel Member
- 2014 Centers for Disease Control and Prevention, Guidelines for antiretroviral post-exposure prophylaxis after sexual, injection drug use, or other non-occupational exposure to HIV. Consultant
- 2015 NICHD/NIH 2015/01 ZRG1 AARR-F (45) Program Project: AIDS and AIDS Related Research. Peer Review Panel Chair
- 2015 NIH 2016/01 ZRG1 AARR-G (54) R Special Emphasis Panel/Scientific Review group member
- 2016 2016/05 ZHD1 DSR-A (52) 1: National Institute of Child Health and Human Development Special Emphasis Panel member
- 2016 Food and Drug Administration Pediatric Advisory Committee Meeting April 12, 2016, Invited Expert Consultant
- 2016-2019 Centers for Disease Control and Prevention (CDC)/Health Resources and Services Administration (HRSA) Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment (CHACHSPT) member, appointed at the request of HRSA.
- 2016-2020 FDA Pediatric Advisory Committee, member, appointed at the request of the FDA
- 2017-2019 Centers for Disease Control and Prevention (CDC)/Health Resources and Services Administration (HRSA) Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment (CHACHSPT), Viral Hepatitis Workgroup, Co-Chair.
- 2018-2020 Member, Scientific Committee of the Adolescent Medicine Trials Network for HIV/AIDS Intervention (NICHD research network).

STATE ADVISORY COMMITTEES AND/OR ACTIVITIES

- 1994-1995 Co-Chair, Workgroup on Perinatal Transmission of HIV, Tertiary Care Committee of the Wisconsin Association of Perinatal Care, Madison, WI
- 1995-1996 Co-Chair, Wisconsin Statewide Workgroup on HIV Education and Testing in the Perinatal Period, Madison WI.
- 1999 Member, Clinical Guidelines Task Force, Wisconsin Antibiotic Resistance Network. Marshfield Clinic and Wisconsin State Division of Health, Madison, WI.
- 2001-2002 Co-Chair, Workgroup on Perinatal Transmission of HIV, Tertiary Care Committee of the Wisconsin Association of Perinatal Care, Madison, WI

COMMUNITY ADVISORY COMMITTEES OR ACTIVITIES

- 1990 Member, Milwaukee Metropolitan AIDS Planning Project, Provider Concerns Task Force
- 1991-2004 City of Milwaukee Pediatric HIV Coordinating Committee
- 1991-1997 Steering Committee of the AIDS Coalition of Milwaukee
- 1991-1999 Milwaukee HIV Services Consortium

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Prior:

- 1991 Established the Dr. Elaine Kohler Fund for Humanity in Medicine, a \$250,000 endowment for research in Pediatric Critical Care Medicine, with the Children's Hospital of Wisconsin Foundation.
- 1992 Enhanced the endowment for research in Pediatric Critical Care Medicine at the Children's Hospital of Wisconsin Foundation, as the Steigleider Trust contributed endowment funding of \$125,000 for research and education in Pediatric Critical Care.
- 1994 Pelz family endowment of \$25,000 to support the Pediatric HIV Care Program at Children's Hospital of Wisconsin. Multiple other Children's Hospital Foundation Grants to support the WI HIV Primary Care Support Network
- 1992-1995 SHARE WITH KIDS Program: Needs assessment for Pediatric/Adolescent HIV care program in Milwaukee, WI. Hemophilia-Pediatric AIDS Special Initiative, Maternal and Child Health Program Grant Number MCH-55HP52-01-0. \$73,000 yearly for 3 years (\$219,000 total granted). Janice Hand, Program Director; Kathleen Marquardt, Project coordinator; Dr Havens, Medical Director.
- 1992 Pediatric HIV Care Program funding, program for Children with Special Health Care Needs. \$28,000.
- 1992 \$6,000 grant from the Pediatric AIDS Foundation to support the Pediatric HIV Care Program at Children's Hospital of Wisconsin.
- 1993 Primary CARRE Project: Maternal and Child Health Bureau Pediatric/Adolescent HIV/AIDS Demonstration Project Grant for statewide program to enhance the care of HIV-infected patients in primary care settings throughout Wisconsin. \$125,000 granted; Dr. Havens, medical director and co-primary investigator.
- 1993-1997 Received grant of \$4,000 yearly for 5 years from the Stackner Family Foundation to support the Pediatric HIV Care Program at Children's Hospital of Wisconsin.
- 1994 Wisconsin HIV Primary Care Support Network for Children, Adolescents, and Families. Maternal and Child Health Bureau Pediatric/Adolescent HIV/AIDS Demonstration Project Grant for statewide program to enhance the care of HIV-infected patients in primary care settings throughout Wisconsin. \$125,000 granted; Dr. Havens, medical director and co-primary investigator.
- 1995 Primary Prevention of Developmental Disabilities Grant to educate providers and consumers about prevention of HIV infection in children. \$5,000 grant total.
- 1995-1996 State of Wisconsin HIV/AIDS Program contract to perform statewide teaching/training concerning recommendations for universal counseling and HIV testing for pregnant women in the state of Wisconsin. \$45,000 grant total. Principal investigator.
- 1995-1996 Children's Hospital of Wisconsin Foundation Grant \$10,850 for Family Satisfaction

- Project, to measure the perception of care delivery by families enrolled in the HIV Primary Care Support Network. Co-principal investigator.
- 1995-1998 Wisconsin HIV Primary Care Support Network. Maternal and Child Health Bureau Pediatric/Adolescent HIV/AIDS Demonstration Project Grant for statewide program to enhance the care of HIV-infected patients in primary care settings throughout Wisconsin. \$250,000 granted yearly for 3 years; Dr. Havens, medical director and co-principal investigator.
- 1997-1998 State of Wisconsin/Centers for Disease Control and Prevention Enhanced HIV/AIDS Surveillance Project for Pregnant Women and Children. Principal investigator. \$135,000 yearly grant total.
- 1996-1999 Bureau of Health Professions General Internal Medicine/General Pediatrics Faculty Development Grant. Dr. Havens receives \$4,000 support for teaching principles of Epidemiology and Clinical Research to faculty in Internal Medicine and Pediatrics.
- 1998-2001 Ryan White CARE Act Title IV grant to support the WI HIV Primary Care Support Network: \$405,443 yearly for 3 years. Medical director.
- 2000-2001 Ryan White CARE Act Title II Grant to support the WI HIV Primary Care Support Network. \$109,603 yearly. Medical Director
- 1999-2001 African American Children's Initiative grant to support the WI HIV Primary Care Support Network: \$95,000.
- 1999-2001 Ryan White CARE Act Title IV supplemental grant to support the WI HIV Primary Care Support Network: \$75,000 yearly for 2 years. Medical director.
- 2001-2003 Ryan White CARE Act Title II grant to support the WI HIV Primary Care Support Network: \$109,603 yearly. Medical director
- 2002-2003 Therapeutic Leadership Group of the Adolescent Medicine Leadership Group of the Adolescent Medicine Trials Network for HIV/AIDS Intervention. NIH grant number: U01 HD40533-02. \$32,976
- 2001-2003 Ryan White CARE Act Title IV grant to support the WI HIV Primary Care Support Network: \$663,873 yearly for 3 years. Second year \$746,436. Third year \$856,276. Medical director - 10% funded effort
- 2003-2004 Ryan White CARE Act Title II grant to support the WI HIV Primary Care Support Network: \$86,080. Medical director - 2.16% funded effort
- 2003-2004 Therapeutic Leadership Group of the Adolescent Medicine Leadership Group of the Adolescent Medicine Trials Network for HIV/AIDS Intervention. NIH grant number: U01 HD40533-03. \$36,655 - 10% funded effort
- 2003-2004 Pediatric AIDS Clinical Trials Group. Affiliate of the Children's Memorial Hospital (Chicago) PACTU. NIH grant number U01-AI041089 - 3% funded effort, 8% unfunded effort
- 2004-2008 Protocol Chair, Pediatric AIDS Clinical Trials Group study P1038: "A phase I/II Safety, Tolerability, and pharmacokinetic study of high dose lopinavir/ritonavir with or without saquinavir in HIV infected pediatric subjects previously treated with protease inhibitors. Approved, 2004
- 2004-2005 Ryan White CARE Act Title II grant to support the WI HIV Primary Care Support Network: \$86,080. Medical director – 1.42% funded effort
- 2004-2005 Therapeutic Leadership Group of the Adolescent Medicine Leadership Group of the Adolescent Medicine Trials Network for HIV/AIDS Intervention. NIH grant number: U01 HD40533-04. \$38,009 - 10% funded effort
- 2004-2005 Pediatric AIDS Clinical Trials Group. Affiliate of the Children's Memorial Hospital (Chicago) PACTU. NIH grant number U01-AI041089 - 3% funded effort, 8%

- unfunded effort
- 2004-2007 Ryan White CARE Act Title IV grant to support the WI HIV Primary Care Support Network: \$856,276 yearly for 3 years. Medical director - 10% funded effort
- 2005 Pediatric HIV Treaters' Data Collection Presentation Template. Midwest AIDS Training & Education Center, University of Illinois at Chicago grant number 5 H4AHA00062-03, \$6,260.
- 2005-2007 Protocol Chair, Adolescent Trials Network study 056, "Pharmacokinetics of once daily antiretroviral therapy regimens containing tenofovir and atazanavir/ritonavir in adolescents and young adults with HIV infection" \$74,498. 10% funded effort
- 2005-2006 Ryan White CARE Act Title II grant to support the WI HIV Primary Care Support Network: \$89,402. Medical director – 1.38% funded effort
- 2005-2006 Therapeutic Leadership Group of the Adolescent Medicine Leadership Group of the Adolescent Medicine Trials Network for HIV/AIDS Intervention. NIH grant number U01 HD40533-05 \$21,325 - 5% funded effort
- 2006-2016 Therapeutic Leadership Group of the Adolescent Medicine Leadership Group of the Adolescent Medicine Trials Network for HIV/AIDS Intervention (ATN). NIH grant number U01 HD40533-05. 10% funded effort
- 2005-2006 Pediatric AIDS Clinical Trials Group. Affiliate of the Children's Memorial Hospital (Chicago) PACTU. NIH grant number U01-AI041089 - \$11,250, 2.87% funded effort
- 2005-2006 Preventing Perinatal HIV Transmission-Wisconsin Provider Education Series. March of Dimes-Wisconsin Chapter Community Award, \$16,663.
- 2006-2007 Ryan White CARE Act Title II grant to support the WI HIV Primary Care Support Network: \$150,600. Medical director – 5% funded effort
- 2007-2008 Ryan White CARE Act Part D expansion grant to support revisions to data system of the WI HIV Primary Care Support Network: \$74,981 for 1 year. Medical director – 2.8% funded effort
- 2007-2010 Protocol Chair, Adolescent Trials Network study 063, "A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D Supplement to Improve Tubular Reabsorption of Phosphate and Decrease Bone Turnover in Adolescents and Young Adults with HIV Infection Being Treated with Antiretroviral Therapy Containing Tenofovir Compared to Those Being Treated with Antiretroviral Therapy Not Containing Tenofovir" \$1,715,560. 10% funded effort.
- 2008-2009 Ryan White CARE Act Part D expansion grant to support electronic connections of outside laboratory data to the revised data system of the WI HIV Primary Care Support Network: \$74,981 for 1 year. Medical director – 2.8% funded effort
- 2007-2012 Ryan White CARE Act Part D grant to support the WI HIV Primary Care Support Network: \$847,712 yearly for 5 years. Medical director – 1.1% funded effort
- 2007-2012 Ryan White CARE Act Part B grant to support the WI HIV Primary Care Support Network: \$210,600. Medical director – 4.5% funded effort
- 2011-2012 Protocol chair, Adolescent Trials Network study "Fibroblast Growth Factor 23 relationships to Parathyroid Hormone, Vitamin D, Calcium, and Phosphate", a sub-analysis of ATN 063. \$77,658. 3% funded effort.
- 2012-2014 Protocol chair, Adolescent Trials Network study "Effect of Vitamin D Treatment on Soluble Mediators of Inflammation: ATN 063 Further Laboratory Studies and Analysis", a sub-analysis of ATN 063. \$180,670. 5% funded effort.
- 2012-2015 Ryan White CARE Act Part D grant to support the WI HIV Primary Care Support Network: \$847,713 yearly for 3 years. Medical director – 4-5% funded effort

- 2012-2018 Ryan White CARE Act Part B grant to support the WI HIV Primary Care Support Network: \$200,000. Medical director – ≈4% funded effort
- 2015-2017 Ryan White CARE Act Part D grant to support the WI HIV Primary Care Support Network: \$847,713 yearly for 3 years. Medical director – 4-5% funded effort
- 2012-2017 Protocol Chair, Adolescent Trials Network study 109 “A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU Every 4 weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth with HIV Infection Being Treated with Tenofovir-Containing Combination Antiretroviral Therapy: A Multi-Center Study of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)”. \$3,282,191. 10% funded effort.
- 2012-2017 Protocol Chair, Adolescent Trials Network Study 117 “Renal, Endocrine, and Bone Changes in Response to Treatment with Coformulated Emtricitabine - Tenofovir for Pre-Exposure HIV Prophylaxis (PrEP) in HIV Uninfected Young Men Who Have Sex with Men. Sub-Study of ATN 110 and/or ATN 113: A Multi-Center Study of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)”. \$1,032,941. 10% funded effort.
- 2016-2018 Ryan White CARE Act Part B grant to support the WI HIV Primary Care Support Network: \$250,000. Medical director – ≈4% funded effort

Active:

- 2015-Present Consultant, Clinical Consultation Center Perinatal HIV Hotline and HIV/AIDS Management Hotline, University of California, San Francisco (HRSA subcontract). 3% funded effort
- 2017-2022 Grant H12HA24811 Havens (PI). Ryan White CARE Act Part D grant to support the WI HIV Primary Care Support Network: \$840,147 yearly for 3 years, with 2 year extension. Medical director – 4-5% funded effort
- 2018-2021 Ryan White CARE Act Part B grant to support the WI HIV Primary Care Support Network: \$535,000. Medical director – ≈4% funded effort
- 2018-2020 Grant #:5U24HD089880-03
Title: Adolescent Medicine Trials Network for HIV/AIDS Intervention (ATN) coordinating Center
PI: Lisa LaVange
Role: Member, ATN Scientific Committee, 10% funded effort

INVITED LECTURES/WORKSHOPS/PRESENTATIONS OUTSIDE WISCONSIN, EXTRAMURAL INVITED LECTURES IN WISCONSIN, AND INTRAMURAL LECTURES: See Appendix

COMMITTEE SERVICE:

Medical College of Wisconsin -- College-wide

- 1991-1992 Dean's Physical Medicine and Rehabilitation Task Force
- 1994 Department of Preventive Medicine Chairman Search Committee
- 1994-1999 Epidemiology Graduate Program Committee

1994-1999 Health Policy Institute Executive Committee
 2004-2005 Rank and Tenure Committee
 2005-2006 Ad-Hoc Committee on the Fourth Pathway
 2006-2007 Department of Population Health, Chair search committee member
 2008-2009 Department of Population Health, Chair search committee member
 2008 Translational scientific peer review panel, CTSI/AHW grants, MCW
 2010 Global Health Advisory Committee
 2012-2014 Central Funds Workgroup of the Institutional Financial Advisory Committee
 2014-2018 Center for International Health Program Advisory Committee

Medical College Committees -- Department of Pediatrics

1987 Faculty Retreat Committee
 1987-1991 Lab Space and Equipment Committee
 1995-2002 Department of Pediatrics Research Committee
 1997-1998 Interim Board of Directors, Pediatric/Children's Specialty Group
 1998-2012 Board of Directors, Pediatric Specialty Group (PSG) then Children's Specialty Group (CSG)
 1998-2006 Billing and Collections Subcommittee of the PSG/CSG
 2003-2015 Children's Specialty Group: Finance Committee (co-chair 2003-2006)
 2003-2015 Children's Specialty Group Contracting Committee member
 2004-2005 Innovation Task Force: Co-chair of Patient Care Group and Chair of Co-chairs groups
 2005-present Department of Pediatrics Promotions Committee
 2010 Children's Research Institute Clinical Effectiveness Research Task Force
 2011 Downtown Health Center Working Group Chair
 2013-2018 Children's Specialty Group Workforce and Position Review Committee member
 2013 Department of Pediatrics Scholarly Activity Committee chair
 2013 Children's Specialty Group Physician's Assistant Excellence Award Review Committee
 2016 Department of Pediatrics Genetics Section Chief Search Committee

Children's Hospital of Wisconsin

1987-1988 Utilization and Quality Review Committee
 1987-2006 Infection Control Committee
 1987-1992 Drug Usage Review Committee
 1989-2001 Pharmacy and Therapeutics Committee
 1990-1991 Laboratory Advisory Committee
 1990-1995 Nutritional Support Committee
 1990-1996 Medical Records Steering Committee
 1992 Central Venous Line Complication Task Force
 1992-1993 Central Venous Line Complication Committee Chair
 1994-1996 Central Venous Line Quality Improvement Task Force Co-Chair
 2006-2010 Data Safety Monitoring Board, Children's Hospital of Wisconsin
 2011-2017 Electronic Health Record transition committees and data/records committees
 2014-present Children's Research Institute Grants reviewer

MEDICAL COLLEGE TEACHING ACTIVITIES:

Medical College Teaching -- Medical Students or Pre-Medical Students

1988	Medical Microbiology Conference Group Leader
1989-1993	Freshman Biostatistics Course (M1): Lecture on Infectious Diseases Epidemiology
1996	General Pathology Course (Pathology 200) lecture on Infectious Diseases Epidemiology.
2001-2015	Preceptor for college students in the SPUR program, one per year

Medical College Teaching -- Residents

1987-1989	PL-3 Teaching Conferences, monthly
1987-2001	Daily lectures to residents when on call in PICU (to 1995) or Intermediate ICU (1996-2001).
1994-Present	Weekly attendance at PL-3 "Senior Rounds" teaching conference (twice weekly since 2008).
1995-2000	PL-3 Journal Club adviser
2001-2006	Once or twice monthly lectures on infectious diseases topic to residents and medical students on Intermediate ICU rotation

Medical College Teaching -- Epidemiology Graduate Students

1987-1993	Active participant in weekly seminar for graduate students in Department of Biostatistics and Clinical Epidemiology (Biostatistics 200)
1995-2011	Research Methods Workshop (see below)
1993	Advanced Topics in Epidemiology (Biostatistics 202): Series on Infectious Diseases Epidemiology for Biostatistics/ Clinical Epidemiology Graduate course.
1992-1993	Graduate School advisor/ thesis Committee for Ramesh Sachdeva, candidate for Master of Science degree in Biostatistics/Clinical Epidemiology, MCW.
1994-1996	Graduate School advisor/ thesis committee for Alan Burkowsky, candidate for Master of Science degree in Epidemiology, MCW.
1995	Infectious Diseases Epidemiology Graduate Seminar (Epi 270: 1 credit). Graduate Program in Epidemiology, Medical College of Wisconsin.
1995-1997	Graduate School advisor/ thesis committee for Kay Sighting, candidate for Master of Science degree in Epidemiology, MCW.
1995-1998	Active participant in weekly seminar for graduate students in the Health Policy Institute graduate program in Epidemiology.
1997	Thesis Committee for Cheryl Flynn, M.D., candidate for Master of Science degree in Epidemiology, MCW.
1997	Infectious Diseases Epidemiology Graduate Seminar (Epi 270: 1 credit). Graduate Program in Epidemiology, Medical College of Wisconsin.
1997-1999	Graduate School advisor/ thesis committee for Matthew Scanlon, M.D., candidate for Master of Science degree in Epidemiology, MCW.
1999	Thesis Committee for Raj Nijhawan, M.D., candidate for Master of Science degree in Epidemiology, MCW.
2000	Thesis Committee for Yolanda Rainge, M.D., candidate for Master of Science degree in Epidemiology, MCW.
2000-03	Graduate School advisor/ thesis committee for Kelly Skoumal (Tieves), M.D., candidate for Master of Science degree in Epidemiology, MCW.
2005-2006	Thesis committee for Noah Leigh, candidate for Master of Science degree in Epidemiology, MCW
2007-2008	Thesis committee for Rupali Fuldeore, candidate for Master of Science degree in

Medical College Teaching -- Fellows and Faculty

- 1990-2011 Research Methods Workshop Co-Director. Initially a course for Clinical Fellows and Medical College Faculty, has also been for Graduate Credit in Epidemiology since 1995. Given by members of the Departments of Pediatrics, Internal Medicine, and Family Medicine. 20-36 students yearly.
- 1996-1999 Medical College of Wisconsin Faculty Development Program, Lecture series on Conducting Clinical Research, to Faculty in Pediatrics, Family and Community Medicine, and General Internal Medicine.
- 1998-2003 Academic Fellowship in Primary Care Research (National Research Service Award): Program steering committee and research faculty.
- 1998-1999 Designing Clinical Research: A Short Course. Series of 6 lecture and discussion sessions for faculty in Pediatric Critical Medicine and Pediatric Emergency Medicine.
- 2005-present Scholarship oversight committees for fellows in the Department of Pediatrics (various divisions)
- 2015-present Faculty, Department of Pediatrics Grant Writing Retreat, a three-day workshop for MCW Faculty to improve grant-writing skills

Medical College Teaching -- Community

- 2002-2017 Co-Director, "HIV Treaters Conference". Organized for practitioners caring for persons with HIV infection throughout southeastern WI: a monthly meeting to present cases and discuss issues in HIV treatment. Initially in Milwaukee/southeastern WI, in 2004 expanded via video link to include University of Wisconsin-Madison School of Medicine, and Infectious Diseases practitioners in Green Bay, and by 2012 also included sites in La Crosse and more sites in Madison and Milwaukee.
- 2004-2009 "Pediatric HIV Treaters Conference". Organized with Dr. Laura Hoyt (Minneapolis) and MATEC-Minnesota. Monthly case presentations via telephone for practitioners caring for children and adolescents with HIV throughout the Midwest (WI, MN, MI, IL, IN, MO, IA). We developed the data presentation software for the calls. I participate monthly

Less formal teaching relationships, not associated with a specific degree program or trainee group, are not reported, or are reflected in lists of presentations or manuscripts.

BIBLIOGRAPHY

REFEREED JOURNAL PUBLICATIONS/ORIGINAL PAPERS

1. **HAVENS PL.** Comparative zone electrophoresis and mating experiments in the taxonomy of Mucor hiemalis. Mycotaxon 1976; 4:218-232.
2. Christie CDC, **HAVENS PL**, Shapiro ED. Bacteremia with group A Streptococci in childhood. AJDC 1988; 142:559-561. PMID: 3282430

3. Leung DY, Moake JL, **HAVENS PL**, Kim M, Pober JS. Lytic anti-endothelial cell antibodies in haemolytic uraemic syndrome. *Lancet* ii 1988; 183-186. PMID: 2899661
4. **HAVENS PL**, O'Rourke PP, Hahn J, Higgins J, and Walker AM. Laboratory and clinical variables to predict outcome in hemolytic uremic syndrome. *AJDC* 1988; 142:961-964. PMID: 3414627
5. **HAVENS PL**, Splaingard ML, Bousounis D, Hoffman GM. Survival after chloroquine ingestion in a child. *J Toxicol-Clin Toxicol* 1988; 26:381-388. PMID: 2848136
6. Hahn JS, **HAVENS PL**, Higgins JJ, O'Rourke PP, Estroff JA, Strand R. Neurological complications in hemolytic uremic syndrome. *J Child Neurol* 1989;4:108-113. PMID: 2715605
7. Splaingard ML, Gaebler D, **HAVENS PL**, Kalichman M. Outcome in children with severe brain injury requiring both tracheostomies and gastrostomies. *Arch Phys Med Rehabil* 1989;70:318-321. PMID: 2930347
8. **HAVENS PL**, Sty JR, Wells RG. Gallium-67 Imaging: chloroquine overdose. *Clinical Nuclear Medicine* 1989;14:135. PMID: 2731395
9. **HAVENS PL**, Hoffman GM, Sheth KJ. The homogeneous nature of the hemolytic uremic syndrome. *Clin Pediatrics* 1989;28:482-483. PMID: 2791440
10. **HAVENS PL**, Garland JS, Brook MS, Dewitz BA, Stremski ES, Troshynski TJ. Trends in mortality in children hospitalized with meningococcal infections, 1957-1987. *Pediatr Infect Dis J* 1989; 8:8-11. PMID: 2922245
11. **HAVENS PL**, Wendelberger KJ, Hoffman GM, Lee MB, Chusid MJ. Corticosteroids as adjunctive therapy in bacterial meningitis: A meta-analysis of clinical trials. *AJDC* 1989;143:1051-1055. PMID: 2773883
12. Losek JD, Dewitz-Zink BA, Melzer-Lange M, and **HAVENS PL**. Epiglottitis: Comparison of signs and symptoms in children less than two years and older children. *Ann Emerg Med* 1990;19:55-58. PMID: 2297156
13. Rutledge SL, **HAVENS PL**, Haymond MW, McLean RH, Kan JS, Brusilow SW. Neonatal Hemodialysis: Effective therapy for the encephalopathy of inborn errors of metabolism. *J Pediatr* 1990;116:125-128.
14. Casper JT, Ash RA, Kirchner P, Hunter JB, **HAVENS PL**, Chusid MJ. Successful treatment of an HLA-deficient SCIDS patient ("Bare lymphocyte syndrome") with an unrelated bone marrow transplant. *J Pediatr* 1990;116:262-265.
15. *Garland JS, Rice TB, Wendelberger KJ, **HAVENS PL**: Presentation and course of Group A Streptococcal supraglottitis. *Wis Med J* 1991;90:55-57.
16. *Torres A, Krilov LR, Jacobsen JM, Kelly KJ, and **HAVENS PL**. Reduced environmental

- exposure to aerosolized ribavirin using a simple scavenging system. *Pediatr Infect Dis J* 1991;10:217-21.
17. *Garland JS, Dunne WM, **HAVENS PL**, Hintermeyer M, Bozette MA, Wincek J, Bamberger T, Seavers M. Peripheral intravenous catheter complications in critically ill children: a prospective study. *Pediatrics* 1992;89:1145-50.
 18. **HAVENS PL**, Dunne WM, and Burd EM. Effects of human intravenous immune globulin on diarrhea caused by shiga-like toxins I and II in infant rabbits. *Microbiol and Immunol* 1992;36:1077-1085.
 19. **HAVENS PL**, Butler J, Day SE, Mohr BA, Davis JP, and Chusid MJ. Treating measles: The appropriateness of admission to a Wisconsin children's hospital. *Am J Pub Health* 1993;83:379-384.
 20. Butler JC, **HAVENS PL**, Sowell AL, Huff DL, Peterson DE, Day SE, Chusid MJ, Bennin RA, Circo R, Davis JP. Measles severity and serum retinol (vitamin A) concentration among children in the United States. *Pediatrics* 1993;91:1176-1181.
 21. Chusid MJ, **HAVENS PL**, Coleman CN. Alpha Omega Alpha election and medical school thesis publication: Relationship to subsequent publication rates over 20 year period. *Yale J Biol Med* 1993;66:67-73.
 22. *Gedeit RG, Weigle CGM, **HAVENS PL**, and Werlin SL. Control and variability of gastric pH in critically ill children. *Crit Care Med* 1993;21:1850-55.
 23. Kelly KJ, Pearson ML, Kurup VP, **HAVENS PL**, Byrd RS, Setlock MA, Butler JC, Slater JE, Grammer LC, Resnick A, Roberts M, Jarvis WR, Davis JP, Fink JN. A cluster of anaphylactic reactions in children with spina bifida during general anesthesia: Epidemiologic features, risk factors, and latex hypersensitivity. *J Allergy Clin Immunol* 1994;94:53-61
 24. Dunne WM, Tillman J, **HAVENS PL**. Assessing the need for anaerobic medium for the recovery of clinically significant blood culture isolates in children. *Pediatric Infectious Diseases Journal* 1994;13:203-6.
 25. Sheth KJ, Gill JC, Leichter HE, **HAVENS PL**, Hunter JB. Increased incidence of HLA-B40 group antigens in children with hemolytic-uremic syndrome. *Nephron* 1994;68:433-436.
 26. Madagame ET, **HAVENS PL**, Bresnahan JM, Babel KL, Splaingard ML. Survival and functional outcome of children requiring mechanical ventilation during therapy for acute bacterial meningitis. *Critical Care Medicine* 1995;23:1279-1283.
 27. Kehl KSC, Cicirello H, **HAVENS PL**. Comparison of four different methods for the detection of *Cryptosporidium* species. *J Clin Microbiol* 1995;33:416-418.
 28. Timmons OT, **HAVENS PL**, Fackler J, and the Pediatric Critical Care Study Group. Predicting death in pediatric patients with acute respiratory failure. *Pediatric Critical Care Study Group. Extracorporeal Life Support Organization. Chest* 1995;108:789-97.

29. Chusid MJ, Splaingard ML, Tweddell JS, Rice TB, Adams M, **HAVENS PL**, Kehl KS. Pulmonary tuberculosis following lung-liver transplantation for cystic fibrosis. *Pediatric Infectious Diseases Journal* 1996;15:462-464.
30. Yabut B, Werlin SL, **HAVENS P**, Bohorfoush A, Brown CW, Harb J. Endoscopic retrograde cholangiopancreatography in children with HIV infection. *J Pediatr Gastroent Nutr* 1996;23:624-627.
31. Garland J, Alex C, Gleisberg D, **HAVENS P**. Clinical utility of a glucose reflectance meter for screening neonates for hypoglycemia. *J Perinatology* 1996;16:250-3 (quiz:254-255).
32. **HAVENS PL**, Cuene BE, Hand J, Waters D, Chusid MJ. Structure of a primary care support system to coordinate comprehensive care for children and families infected/affected by HIV in a managed care environment. *Ped Infect Dis J* 1997;16:211-216.
33. **HAVENS PL**, Cuene BE, Holtgrave DR. Lifetime cost of care for children with HIV infection. *Ped Infect Dis J* 1997;16:607-10.
34. **HAVENS PL**, Cuene BE, Hand JR, Gern JE, Sullivan BW, Chusid MJ. Effectiveness of intensive nurse case management in decreasing vertical transmission of Human Immunodeficiency Virus infection in Wisconsin. *Ped Infect Dis J* 1997;16:871-5.
35. *Spack L, **HAVENS PL**, Griffith OW. Measurements of total plasma nitrite and nitrate in pediatric patients with the systemic inflammatory response syndrome. *Crit Care Med* 1997;25:1071-8.
36. *Spack L, Gedeit R, Splaingard M, **HAVENS P**. Failure of aggressive therapy to alter outcome in pediatric near drowning. *Ped Emergency Care* 1997;13:98-102.
37. *Thakker JC, Splaingard M, Zhu J, Babel J, Bresnahan J, **HAVENS PL**. Survival and functional outcome of children requiring endotracheal intubation during therapy for severe traumatic brain injury. *Crit Care Med* 1997;25:1396-1401.
38. Cicirello HG, Kehl KS, Addiss DG, Chusid MJ, Glass RI, Davis JP, **HAVENS PL**. Cryptosporidiosis in children during a massive waterborne outbreak, Milwaukee, Wisconsin: Clinical, Laboratory, and epidemiologic findings. *Epidemiol Infect* 1997;119:53-60.
39. Kehl, KS, **HAVENS P**, Behnke CE, Acheson DW. Evaluation of the Premier EHEC assay for detection of Shiga toxin-producing *Escherichia coli*. *J Clin Microbiol* 1997;35:2051-4.
40. **HAVENS PL**. Acute otitis media in children: What next when first-line therapy fails? *Consultant* 1998;38:2681-2684, 2687-2690.
41. *Balasubramanyan N, **HAVENS PL**, Hoffman GM. Unmeasured anions identified by the Fencl-Stewart method predict mortality better than base excess, anion gap, and lactate in patients in the pediatric intensive care unit. *Crit Care Med* 1999;27:1577-81.

42. Kehl SC, **HAVENS PL**, Chusid MJ. Prevalence of penicillin-resistant and multi-drug resistant *Streptococcus pneumoniae* at a children's hospital. *Wi Med J* 1999;98:42-5.
43. *Beckmann KR, Melzer-Lange MD, Cuene B, Dietz M, **HAVENS PL**. The effectiveness of a followup program at improving human immunodeficiency virus testing in a pediatric emergency department. *Wi Med J* 2002;101:30-34.
44. Wells RG, **HAVENS PL**. Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. *Radiology* 2003;228:370-378.
45. Ramirez S, Hild TG, Rudolph CN, Sty JR, Kehl SC, **HAVENS P**, Henrickson K, Chusid MJ. Increased diagnosis of Lemierre syndrome and other *Fusobacterium necrophorum* infections at a children's hospital. *Pediatrics*. 2003;112:e380-e385.
46. *Rao AR, Splaingard MS, Gershan WM, **HAVENS PL**, Thill A, Barbieri JT. Detection of *Pseudomonas aeruginosa* type-III antibodies in children with tracheostomies. *Pediatric Pulmonology* 2005;39:402-407.
47. Franklin S, Lim HJ, Rennie KM, Eastwood D, Cuene B, **HAVENS PL**. Longitudinal Intellectual assessment of children with HIV infection. *Journal of Clinical Psychology in Medical Settings* 2005;12:367-76.
48. *Skelton JA, **HAVENS PL**, Werlin SL. Nutrient deficiencies in tube fed children. *Clin Pediatr* 2006;45:37-41
49. *Skelton JA, Busey SL, **HAVENS PL**. Weight and Health Status of Inner City African American Children: Perceptions of Children and their Parents. *Body Image* 2006;3:289-293
50. *Lee KJ, **HAVENS PL**, Sato TT, Hoffman GM, Leuthner SR. Assent for treatment: clinician knowledge, attitudes, and practice. *Pediatrics* 2006;118:723-730
51. Destino L, Sutton DA, Helon AL, **HAVENS PL**, Thometz JG, Willoughby RE, Chusid MJ. Severe osteomyelitis caused by *Myceliophthora thermophila* after a pitchfork injury. *Ann Clin Micro Antimicrob* 2006; 5:21.
52. *Hanson SJ, Punzalan RC, Ghanayem N, **HAVENS PL**. Prevalence of heparin-dependent platelet antibodies in children after cardiopulmonary bypass, *Pediatric Crit Care Med* 2007;8:358-61
53. Persaud D, Palumbo P, Ziemniak C, Chen J, Ray SC, Hughes M, **HAVENS P**, Purswami M, Guar AH, Chadwick EG, and the Pediatric AIDS Clinical Trials Group P1030 Team. Early archiving and predominance of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. *J Infect Dis* 2007;195:1402-10.
54. Gordon JB, Colby HH, Bartelt T, Jablonski D, Krauthoefer ML, **HAVENS P**. A tertiary care-primary care partnership model for medically complex and fragile children and youth with special health care needs. *Arch Pediatr Adolesc Med* 2007;161:937-944.

55. Franklin JA, Lim HJ, **HAVENS PL**. Longitudinal academic and social progress of children with perinatally acquired HIV. *Journal of Clinical Psychology in Medical Settings*, 2007;14:335-343.
56. **Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani, RM, Liu NX, Muenz LR, Harris DR, **HAVENS PL**, and the Adolescent Trials Network for HIV/AIDS Interventions. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir/ritonavir in adolescents and young adults with HIV infection – study ATN056. *Antimicrob Agents Chemother*, 2008;52:631-37
57. *Petroll A, Galletly C, **HAVENS PL**, Kwiecinski MF, Pinkerton S. Updated CDC guidelines for HIV testing: A review for Wisconsin Practitioners. *Wisconsin Med J* 2008;107:84-90
58. **Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, and **HAVENS PL**, for the PACTG 1038 Team. Pharmacokinetics of High-Dose Lopinavir/Ritonavir with and without Saquinavir or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors – Study PACTG P1038. *Antimicrobial Agents Chemother* 2008;52:3276-3283.
59. *Hanson SJ, Kim M, Berens R, Hoffman GM, **HAVENS PL**. Effect of Volume Resuscitation on Regional Perfusion in Dehydrated Pediatric Patients as Measured by Two-site Near-infrared Spectroscopy. *Pediatric Emergency Care* 2009;25:150-153.
60. Kumar S, Chusid MJ, Willoughby RE, **HAVENS PL**, Kehl SC, Ledebouer NA, Li SH, Henrickson KJ. Introduction of a novel swine-origin influenza A (H1N1) virus into Milwaukee, Wisconsin in 2009. *Viruses* 2009;1:72-83.
61. Mitchell ME, McManus M, Dietz J, Camitta, BM, Szabo S, **HAVENS PL**. *Absidia corymbifera* endocarditis: Survival after treatment of disseminated mucormycosis with radical resection of tricuspid valve and right ventricular free wall. *J Thorac CV Surg* 2010;139:e71-2
62. *Hanson SJ, Punzalan R, Sato, T, Greenup R, Liu H, **HAVENS PL**. Incidence and risk factors for venous thromboembolism in critically ill children after trauma. *J Trauma*, 2010;68:52-6.
63. *Gupta S, **HAVENS PL**, Southern JF, Firat SY, Jogal SS. Epstein-Barr virus associated intracranial leiomyosarcoma in an HIV positive adolescent. *J Pediatr Hematol Oncol* 2010 Mar 10 (epub).
64. Kumar S, Chusid MJ, Willoughby RE, **HAVENS PL**, Kehl SC, Ledebouer NA, Simpson P, Vandyke M, Davis E, Gaffney L, Li SH, Bose ME, Henrickson KJ. Epidemiologic observations from passive and targeted surveillance during the first wave of the 2009 H1N1 influenza pandemic in Milwaukee, WI. *Viruses* 2010;2(4):782-795

65. Kumar S, **HAVENS PL**, Chusid MJ, Willoughby RE Jr, Simpson P, Henrickson KJ. Clinical and epidemiologic characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection. *Pediatr Infect Dis J* 2010(7): 591-4
66. *Gupta S, Cogbill CH, Gheorghe G, Rao AR, Kumar S, **HAVENS PL**, Camitta BM, Warwick AB. Mycobacterium avium intracellulare Infection Coexistent With Nodular Lymphocyte Predominant Hodgkin Lymphoma Involving the Lung. *J Pediatr Hematol Oncol* 2011 Mar 10 (epub)
67. Hickey CA, Beattie TJ, Cowieson J, Miyashita Y, Strife F, Frem JC, Peterson JM, Butani L, Jones DP, **HAVENS PL**, Patel HP, Wong CS, Andreoli SP, Rothbaum RJ, Beck AM, Tarr PI. Early Volume Expansion during Diarrhea and Relative Nephroprotection during subsequent hemolytic uremic syndrome. *Archives of Pediatrics and Adolescent Medicine* 2011 epub July 22 PMID 21784993.
68. Kumar S, Fan J, Melzer-Lange M, Trost J, **HAVENS PL**, Willoughby RE, Chusid MJ, Henrickson KJ. H1N1 hemagglutinin-inhibition seroprevalence in Emergency Department Health Care Workers after the first wave of the 2009 influenza pandemic. *Pediatr Emerg Care* 2011;27(9):804-7.
69. Baheti G, Kiser JJ, **HAVENS PL**, Fletcher CV. Plasma and intracellular pharmacokinetic analysis of tenofovir in HIV-1 infected patients. *Antimicrob Agents Chemother* 2011; 55(11):5294-9
70. Hanson SJ, Punzalan RC, Christensen MA, Ghanayem NS, Kuhn EM, **HAVENS PL**. Incidence and risk factors for venous thromboembolism in critically ill children with cardiac disease. *Pediatr Cardiol* 2012;33:103-8. PMID: 21927987
71. ****HAVENS PL**, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Mulligan K, the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial. *Clin Infect Dis* 2012;54(7):1013-1025.
72. ****HAVENS PL**, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB, for the the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team. Serum 25-Hydroxyvitamin D Response to Vitamin D3 Supplementation 50,000 IU Monthly in Youth with HIV-1 Infection. *Journal of Clinical Endocrinology & Metabolism* 2012; 97(11): 4004-4013 (epub August 2012).
73. *Chiu YE, **HAVENS PL**, Siegel DH, Ali O, Wang T, Holland KE, Galbraith SS, Lyon VB, Drolet BA. Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity. *J Am Acad Dermatol* 2013 Jul;69(1):40-6 PMID 23415685
74. Hanson SJ, Punzalan RC, Arca MJ, Simpson P, Christensen MA, Hanson SK, Yan K, Braun K, **HAVENS PL**. Effectiveness of clinical guidelines for deep vein thrombosis prophylaxis

in reducing the incidence of venous thromboembolism in critically ill children after trauma. *J Trauma Acute Care Surg* 2012 May;72(5):1292-7 PMID: 22673257

75. ****HAVENS PL**, Kiser JJ, Stephensen CB, Hazra, R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 study team. Association of higher plasma vitamin D binding protein and lower free calcitriol with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: Cause of a functional vitamin D deficiency? *Antimicrob Agents Chemother* 2013 57(11):5619-28 (epub 3 Sept 2013) PMID: 24002093
76. ****Porter TR**, Li X, Stephensen CB, Mulligan K, Rutledge B, Flynn PM, Lujan-Zilbermann J, Hazra R, Wilson CM, **HAVENS, PL**, and Tang, J, for the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 study team. Genetic Associations with 25-Hydroxyvitamin D Deficiency in HIV-1-Infected Youth: Fine-Mapping for the GC/DBP Gene That Encodes the Vitamin D-Binding Protein. *Frontiers in Genetics: Pharmacogenetics and Pharmacogenomics*, 2013, November (4). Article 234: 1-9. doi: 10.3389/fgene.2013.00234.
77. ****HAVENS PL**, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel, J, Pan CG, Woodhouse LR, van Loan MD, Liu N, Lujan-Zilberman J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K, and the Adolescent Medicine Trials Network for HIV/AIDS Intervention (ATN) 063 study team. Vitamin D3 Supplementation Increases Fibroblast Growth Factor-23 in HIV-Infected Youth Treated with Tenofovir Disoproxil Fumarate. *Antiviral Therapy* 2014; 19:613-18 (epub Feb 17 2014) PMID 24535626
78. *Schloemer NJ, Abu-Sultaneh S, Hanson SJ, Yan K, Hoffmann RG, Punzalan RC, **HAVENS PL**. Higher Doses of Low-Molecular-Weight Heparin (Enoxaparin) Are Needed to Achieve Target Anti-Xa Concentrations in Critically Ill Children. *Pediatr Crit Care Med* 2014; 15:e294-9
79. *Hanson SJ, **HAVENS, PL**, Simpson PM, Nugent ML, Wells RG. Intrapleural alteplase decreases parapneumonic effusion volume in children more than saline irrigation. *Pediatric Pulmonology* 2015; 50:1328-35
80. Zembles TN, Thompson NE, Huppler AR, **HAVENS PL**. Development of a voriconazole clinical practice guideline at a pediatric institution. *Journal of the Pharmacy Society of Wisconsin* 2016 Jan/Feb; 31-33
81. Nguyen HS, Foy A, **HAVENS P**. Intracranial subdural empyema after surgery for lumbar lipomyelomeningocele: a rare complication. *Surg Neurol Int.* 2016;7(Suppl 12):S301-4. doi: 10.4103/2152-7806.182388.
82. Zembles TN, Thompson NE, **HAVENS PL**, Kaufman BA, Huppler AR. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger Than 2 Years Old. *Pharmacotherapy* 2016;36:1102-1108: DOI: 10.1002/phar.1829
83. ****HAVENS PL**, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM,

- Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 study team. Decline in Bone Mass with Tenofovir Disoproxil Fumarate/Emtricitabine is Associated with Hormonal Changes in the Absence of Renal Impairment When Used by HIV Uninfected Adolescent Boys and Young Men for HIV Pre-Exposure Prophylaxis. *Clin Infect Dis* 2017;63:317-325. (published online November 15, 2016.) doi:10.1093/cid/ciw765.
84. *Balakrishnan B, Dasgupta M, Gajewski K, Hoffmann RG, Simpson PM, **HAVENS PL**, Hanson SJ. Low near infrared spectroscopic somatic oxygen saturation at admission is associated with need for lifesaving interventions among unplanned admissions to the pediatric intensive care unit. *J Clin Monit Comput* 2018;32:89-96 (online 2017 Mar 3 PMID 28258341)
 85. ****HAVENS PL**, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris RD, Price G, Baker A, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 study team. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with HIV Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial. *Clin Infect Dis* 2018;66:220-8 (online 8/21/2017). PMID: 29020329; doi: 10.1093/cid/cix753
 86. Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, **HAVENS PL**, Rakhmanina N, Capparelli EV. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes across formulations and human development from infancy through adulthood. *J Clin Pharmacol* 2018;58:1604-1617. (online 2018 Sept 25). PMID: 30252146
 87. ****HAVENS PL**, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB, and the Adolescent Medicine Trials Network for HIV/AIDS Intervention (ATN) 117 and 109 study teams. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone. *Antiviral Therapy* 2018;23:623-628 (online Sept 27, 2018). Doi: 10.3851/IMP3269. PMID: 30260797
 88. ****HAVENS PL**, Tamhane A, Stephensen CB, Schuster GU, Gordon CM, Liu, N, Wilson CM, Hosek SG, Anderson PL, Kapogiannis BG, Mulligan K, for the Adolescent Trials Network for HIV/AIDS Intervention Protocol 117 Study team. Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis. *AIDS Research and Human Retroviruses* 2019 Feb;35(2):123-128 (online Oct 3, 2018) <https://doi.org/10.1089/AID.2018.0096>. PMID: 30280906
 89. ****HAVENS PL**, Perumean-Chaney SE, Patki A, Cofield SC, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K. Changes in Bone Mass After Discontinuation of Pre-Exposure Prophylaxis (PrEP) with Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. *Clin Infect Dis* 2019 (online June 8, 2019) *Clin Infect Dis* 2020;70:687-91 <https://doi.org/10.1093/cid/ciz486>; PMID 31179503

90. *Swartz S, Hadjiev J, Kolinski J, Chou E, Allen K, Yan K, **HAVENS PL**. Factors Associated with HSV PCR CSF Testing and Empiric Acyclovir Therapy in Young Febrile Infants. *Clin Pediatr (Phila)* 2019;58:1194-1200. PMID: 31409122
91. *Burek AG, Liljestrom T, Porada K, Matschull L, Pan A, **HAVENS PL**, Goday PS. Nutritional Advancement in the Hospitalized Child After NPO: A Retrospective Cohort Study. *Hosp Pediatr* 2019 Dec 27. PMID 31882443

* The first authors of these publications were trainees or junior faculty supervised at least in part by Dr. Havens at the time the investigations were performed.

** Dr. Havens was Principal Investigator/Protocol Chair

CHAPTERS AND REVIEWS:

1. **HAVENS PL**. Nosocomial infections in the pediatric intensive care unit. Chapter 9, pp 101-111, in: Gioia FR and Yeh TS (eds). *Pediatric Critical Care Clinical Review Series, Part 3*. Society of Critical Care Medicine, 1991.
2. **HAVENS PL**. Nosocomial Pneumonia. in Kaplan SL (ed). *Current Therapy in Pediatric Infectious Disease, Third edition*. 1993. Mosby-Year Book, St. Louis, Mo.
3. **HAVENS PL**. Nosocomial infections in the pediatric intensive care unit. Chapter 9, pp 142-153, in: Stidham GL and Weigle CGM (eds). *Pediatric Critical Care Clinical Review Series, Part 3*. Society of Critical Care Medicine, 1994.
4. **HAVENS PL**. Evaluating medical literature: Clinical epidemiology. in Behrman RE and Kliegman RM (eds), *Nelson Textbook of Pediatrics-15th edition*. W.B. Saunders, 1996: 5-12.
5. **HAVENS PL**. Applying the medical literature to clinical decision making. in Kliegman RM, Nieder ML, and Super DM (eds), *Practical Strategies in Pediatric Diagnosis and Therapy*. W.B. Saunders, 1996: 15-24.
6. **HAVENS PL** and Davis JP. Cryptosporidium and cryptosporidiosis. *Seminars Pediatr Infect Dis* 1996;7:250-257.
7. **HAVENS PL** and Waters, DA. HIV Infection in Children. in Dershewitz RA (ed.), *Ambulatory Pediatric Care, 3rd edition*. Lippincott-Raven, Philadelphia. 1998.
8. **HAVENS PL**. Pediatric AIDS. in Armstrong D and Cohen J (eds), *Infectious Diseases*. Mosby, London. 1999.
9. **HAVENS PL**. Diagnosis of HIV in Newborns. in Armstrong D and Cohen J (eds), *Infectious Diseases*. Mosby, London. 1999.
10. **HAVENS PL**. Meningismus and meningitis. In Kliegman RM, Greenbaum L, Lye P (eds),

Practical Strategies in Pediatric Diagnosis and Therapy second edition . W.B. Saunders, 2002

11. **HAVENS PL.** Pediatric HIV. in Cohen J and Powderly WG (eds), Infectious Diseases, second edition. Mosby, London. 2003.
12. **HAVENS PL.** Diagnosis of HIV in Newborns. in Cohen J and Powderly WG (eds), Infectious Diseases, second edition. Mosby, London. 2003.
13. **HAVENS PL.** Principles of antiretroviral therapy for children with HIV infection. Seminars in Pediatr Infect Dis 2003;14:269-85
14. **HAVENS PL** and Waters D. Management of the infant born to a mother with HIV infection. Chapter for Pediatric Clinics of North America-Normal Newborns, 2004;51:909-937.
15. **HAVENS PL** and Dominguez K. HIV Postexposure Prophylaxis. In Zeichner S, and Read J. (eds) Handbook of Pediatric HIV Care, second edition. Cambridge University Press, 2006.

BOOKS:

1. Waters D, **HAVENS P**, McClellan-Tilson B, Murphy D, Frisby H. Medical Management of Newborns and Infants Born to HIV-Infected Mothers. Wisconsin Department of Health and Social Services, Division of Health. Publication POH 4498 (Rev. 11/92).
2. Waters D, **HAVENS P**, McClellan-Tilson B, Murphy DA, Frisby HR, McIntosh, K. Medical Management of Newborns, Infants, and Children Born to HIV-Infected Mothers. Wisconsin Department of Health and Social Services, Division of Health. Publication POH 4498 (Rev. 10/93).
3. **HAVENS PL**, Waters DA, Cuene BE, McIntosh K, Yogev R. Caring for Infants, Children, Adolescents, and Families with HIV Infection. Wisconsin Department of Health and Social Services, Division of Health. Publication POH 4498 (Rev. 12/95).
4. **HAVENS PL**, Waters DA, Cuene BE, McIntosh K, Yogev R. Caring for Infants, Children, Adolescents, and Families with HIV Infection. Wisconsin Department of Health and Social Services, Division of Health. Publication POH 4498 (Rev. 12/96).
5. **HAVENS PL**, Waters DA, Cuene BE, McIntosh K, Yogev R. Caring for Infants, Children, Adolescents, and Families with HIV Infection. Wisconsin Department of Health and Social Services, Division of Health. Publication POH 4498 (Rev. 3/98, revised 01/01 at www.mew.edu/peds/infectdis "HIV Care Guide).

EDITORIALS / INVITED COMMENTARY:

1. **HAVENS PL.** Meta-analysis redux: steroids and meningitis revisited. *West J Med* 1992;157:84-86.
2. **HAVENS PL.** Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with HIV-1: Commentary. [*JAMA HIV/AIDS* Web site]. 2/29/2000. Available at: <http://www.ama-assn.org.special/hiv/library/library.htm>. Accessed 3/2/2000.
3. Flynn P, **HAVENS P**, Brady M, Emmanuel P, Read J, Hoyt L, Henry-Reid L, Van Dyke R, Mofenson L. Male Circumcision for prevention of HIV and other sexually transmitted diseases. (Commentary) *Pediatrics* 2007;119:821-822
4. **HAVENS PL**, Hazra R. The place of Tenofovir Disoproxil Fumarate in Pediatric Antiretroviral Therapy. *Pediatr Infect Dis J* 2015;34:406-408
5. **HAVENS PL**, Anderson JR. Updated CDC recommendations for universal hepatitis C virus screening among adults and pregnant women: Implications for clinical practice. (Viewpoint) *JAMA* 2020 online April 9. doi:10.1001/jama.2020.3693

LETTERS:

1. **HAVENS PL** and Garland JS. Direct inspection of the epiglottis. *AJDC* 1988;142:1262.
2. **HAVENS PL**, Hoffman GM, Rice TB, Kelly KJ, Day SE, Wendelberger KJ, Chusid MJ. Dexamethasone therapy for bacterial meningitis. *N Engl J Med* 1989;320:464.
3. Sheth KJ, Gill JC, **HAVENS PL**, Leichter HE. Racial incidence of hemolytic-uremic syndrome. *Pediatric Nephrology*. 1995;9:401.
4. *Banwart B, Splaingard ML, Farrell PM, Rock MJ, **HAVENS PL**, Moss J, Ehrmantraut ME, Frank DW, Barbieri JT. Children with cystic fibrosis produce an immune response against Exoenzyme S, a type-III cytotoxin of *Pseudomonas aeruginosa*. *J Infect Dis* 2002;185:269-70.

OTHER PUBLICATIONS (AS MEMBER OF LOCAL, STATE, NATIONAL, OR INTERNATIONAL GROUPS):

1. **HAVENS PL**, Roy B, Burr C. Providing for the care of HIV infected children, adolescents, and their families in the midwestern United States. Summary and proceedings of conference Feb 25, 1993.
2. Wisconsin Association for Perinatal Care. Position statement: Human immunodeficiency virus (HIV) education and testing in the perinatal period. July, 1995. Committee Co-chair.
3. Working Group on Antiretroviral Therapy and Medical Management of Infants, Children, and Adolescents with HIV Infection. Antiretroviral Therapy and Medical Management of

- Infants, Children, and Adolescents with HIV Infection. *Pediatrics* 1998;102:1005-1062. Also published as: Centers for Disease control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. *MMWR* 1998;47(RR-4). Current citation: Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use of Antiretroviral Agents in Pediatric HIV Infection. Updated periodically at www.aidsinfo.nih.gov. Member of writing committee in 1996-1997, and again since 2000. Co-Chair 2003-2006. Co-Chair 2006 (Dec)-2015. Chair 2016-present. Contributed sections to versions published in: 1998, 2001, and every version thereafter.
4. American Academy of Pediatrics Committee on Pediatric AIDS. Education of children with human immunodeficiency virus infection. *Pediatrics* 2000;105:1358-60. Committee member
 5. American Academy of Pediatrics Committee on Pediatric AIDS. Identification and care of HIV-exposed and HIV-infected infants, children, and adolescents in foster care. *Pediatrics* 2000;106:149-53. Committee member
 6. Mofenson LM, and the American Academy of Pediatrics Committee on Pediatric AIDS. Technical report: Perinatal human immunodeficiency virus testing and prevention of transmission. *Pediatrics* 2000;106:e88. Committee member.
 7. American Academy of Pediatrics Committee on Pediatric AIDS and Committee on Adolescence. Adolescents and human immunodeficiency virus infection: the role of the pediatrician in prevention and intervention. *Pediatrics* 2001;107:188-90. Committee member
 8. Wisconsin Association for Perinatal Care. Revised Recommendations for Human immunodeficiency virus (HIV) education and testing in the perinatal period. September, 2002. Committee Co-chair.
 9. **HAVENS PL**, and the American Academy of Pediatrics Committee on Pediatric AIDS. Clinical Report: Postexposure prophylaxis in children and adolescents for nonoccupational exposure to Human Immunodeficiency Virus. *Pediatrics* 2003;111:1475-1489. Primary author and committee member.
 10. Read JS and the American Academy of Pediatrics Committee on Pediatric AIDS. Technical Report: Human Milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States. *Pediatrics* 2003;112:1196-1205. Committee Member
 11. King SM, and the American Academy of Pediatrics Committee on Pediatric AIDS and the Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Evaluation and treatment of the human immunodeficiency virus-1-exposed infant. *Pediatrics* 2004;114:497-505. Committee member.
 12. Human Immunodeficiency Virus Infection. First editor of this chapter for the “Red Book” 27th edition, American Academy of Pediatrics Report of the Committee on Infectious Diseases. AAP, 2006. Committee chair.

13. Henry-Reid LM, and the American Academy of Pediatrics Committee on Pediatric AIDS. Reducing the risk of HIV infection associated with illicit drug use. *Pediatrics* 2006;117:566 Committee chair.
14. American Academy of Pediatrics Committee on Pediatric AIDS and Section on International Child Health. Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. *Pediatrics* 2007;119:838-845. Lead author and Committee chair.
15. American Academy of Pediatrics. "Covering the bases: Adolescent Sexual Health". 2007. "Pedialink" online educational tool (3 hours CME credit). Lead subject matter expert, lead author of section on sexually transmitted diseases in adolescents and Committee chair.
16. American Academy of Pediatrics Committee on Pediatric AIDS, Havens PL, Mofenson, LM,. Policy Statement. HIV Testing and Prophylaxis to Prevent Mother-to-Child Transmission in the United States. *Pediatrics*, *Pediatrics* 2008;122:1127-34. Lead author and committee chair
17. **HAVENS PL**, Mofenson LM, and the American Academy of Pediatrics Committee on Pediatric AIDS. Clinical Report: Evaluation and Management of the Infant Exposed to Human Immunodeficiency Virus Type 1 in the United States. *Pediatrics*, 2009;123:175-187. Lead author and committee chair
18. Mofenson LM, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009 Sep 4;58(RR-11):1-166. Committee member
19. World Health Organization. Technical Update on treatment optimization: Use of tenofovir disoproxil fumarate in HIV-infected children and adolescents aged 2-18 years: a public health perspective. 2012 (June): available at http://apps.who.int/iris/bitstream/10665/70944/1/9789241503822_eng.pdf. Technical consultant, lead author of initial draft.

OTHER:

1. Database for care of children and adolescents with HIV Infection, now in use in Wisconsin, and adapted for use in Chicago, New Hampshire, and Puerto Rico (Fall, 1997)
2. **HAVENS PL**. Bioterrorism: Background on three possible agents, available online: <http://www.mcw.edu/peds/infectdis/bioterrorism.pdf>. Included in the US Army Medical Department Center & School (AMEDDC&S), Academy Of Health Sciences, Fort Sam Houston, Texas, repository on Homeland Security, 2004
3. **Havens PL**. Smallpox Treatment 2002: Topic of Speculation, available online: http://ftp.cdc.gov/pub/infectious_diseases/iceid/2002/pdf/havens.pdf. Included in the US Army Medical Department Center & School (AMEDDC&S), Academy Of Health Sciences, Fort Sam Houston, Texas, repository on Homeland Security, 2004

4. **HAVENS PL.** Tenofovir DF Use in Children and Youth Ages 2 to 18 years with HIV Infection. World Health Organization (WHO) Data Review “White Paper”. Presented to the Paediatric Antiretroviral Working Group, Pediatric Dosing Guidance Meeting for Treatment 2.0. World Health Organization, Geneva, Switzerland, October, 2011

ABSTRACTS (NOT A COMPREHENSIVE LIST):

1. **HAVENS PL:** Group A streptococcal bacteremia in children. *Ped Res* 20 (4 pt. 2): 311A, 1986.
2. **HAVENS PL, O'Rourke PP, Hahn J, Higgins J, and Walker AM.** Predicting outcome in Hemolytic Uremic Syndrome. Presented to the American Academy of Pediatrics meetings, October 31, 1987, New Orleans, LA.
3. Hahn J, **HAVENS PL**, Higgins J, O'Rourke PP, and Estroff J. Neurologic Complications of Hemolytic Uremic Syndrome. Presented at Child Neurology Society Meetings, October, 1987.
4. Kelly KJ, **HAVENS PL**, Day SE, Hoffman GM, Deacon J, Wolf J. Extracorporeal Membrane Oxygenation (ECMO) in Two Infants with Congenital ECHO-11 Virus pneumonia. Presented at Ross Laboratories Special Conference. Two Great Debates in Neonatology, December 6-8, 1987, p. 137. Loews L'Enfant Plaza Hotel, Washington D.C., 1987.
5. **HAVENS PL**, Sowles PW, Sinner JA, Day SE. Gentamicin Pharmacokinetics of neonates receiving Extracorporeal Membrane Oxygenation. Presented at the CHNMC ECMO Symposium, February 21-28, 1988, Snowmass, Colorado.
6. **HAVENS PL**, Dunne WM, Sheth KJ. Neutralization of E. coli 0157:H7 Vero cell toxins by commercially available human intravenous immune globulin. Presented at the American Society for Microbiology Annual meeting, May 10, 1988, Miami, Florida.
7. **HAVENS PL**, Garland JS, Brook M, Dewitz B, Stremski E, Troshynski T. Trends in mortality and severity of meningococcal disease in children. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, October 23-26, 1988 Los Angeles, California.
8. Leung DYM, Moake JL, **HAVENS PL**, Kim M, Pober JS. Lytic anti-endothelial cell antibodies are present in hemolytic-uremic syndrome (HUS) and differ from those in acute, non-relapsing thrombotic thrombocytopenic purpura (TTP). *Clin Res*, 36:413A. 1988.
9. Losek JD, Dewitz BA, Melzer-Lange M, **HAVENS PL**. Epiglottitis: signs and symptoms in children less than two years. *Ped Res* 1989;25:135A.
10. *Garland J, Dunne W, **HAVENS P**, Hintermeyer M, Bozzette M, Wincek J, Bromberger T, Seavers M. Peripheral intravenous catheter (PVC) complications in children in a Pediatric Intensive Care Unit (PICU). Presented at 29th Interscience Conference on Antimicrobial

Agents and Chemotherapy (ICAAC), 17-20 September 1989, Houston, Texas.

11. Dunne WM, **HAVENS PL**, Counter FT. Fibrinogen (FN) and proteolytic fragments of FN interfere with the adherence of slime-positive Staphylococcus epidermidis (S+SE) to plastic in vitro. Presented at 29th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 1989, Houston, Texas.
12. **HAVENS PL**, Moldovanu JC, Vaughan BC, Chusid MJ. Risk of late infection following transient candidemia. Presented at 29th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 1989, Houston, Texas.
13. *Vaughan BC, Gill JC, **HAVENS PL**, Day SE. Association of the plasma anticoagulant, antithrombin III, and thrombosis following extracorporeal membrane oxygenation. Presented at the 3rd Pediatric Critical Care Colloquium, 26-28 October 1989, Santa Monica, California.
14. **HAVENS PL**, Dunne WM, and Burd EM. Effect of human intravenous immune globulin on diarrhea caused by shiga-like toxins I and II in infant rabbits. Presented at American Society for Microbiology Annual Meeting, May 13-17, 1990, Anaheim, California.
15. *Torres A, Krilov LR, Jacobsen JM, Kelly KJ, and **HAVENS PL**. Reduction of occupational exposure to Ribavirin using a simple scavenging system. Presented at the 4th Pediatric Critical Care Colloquium, 2-4 October, 1990, Waterville Valley, New Hampshire.
16. **HAVENS PL**, Butler JC, Day SE, Mohr BA, and Chusid MJ. Characteristics of 243 children hospitalized with measles during an epidemic in Milwaukee. Presented at 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 21-24 October, 1990, Atlanta, GA.
17. Krilov L, Torres A, Jacobsen J, Karol M, Kelly K, and **HAVENS PL**. A double hood system to prevent escape of ribavirin. Presented at 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 21-24 October, 1990, Atlanta, GA.
18. Burd EM, **HAVENS PL**, Dunne WM. Enzyme linked immunosorbent assay (ELISA) for Shiga-like toxin II based on its binding to the receptor globotriosyl ceramide (Gb₃). Presented at the American Society for Microbiology Annual Meeting, May 5-9, 1991, Dallas, TX.
19. *Sachdeva RC, Day SE, **HAVENS PL**, Weitekamp LA, Vaughan BC. Effect of a protocol to minimize blood donor exposure (DE) in ECMO patients. Presented at the Seventh Annual Children's Hospital National Medical Center ECMO Symposium, February, 1991, Breckenridge, CO.
20. **HAVENS PL**, Burd EM, and Dunne WM. Prevalence of antibody to Shiga-like toxins I and II varies by age and location. Presented at 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 29 September - 2 October, 1991, Chicago, IL.
21. Butler JC, **HAVENS PL**, Sowell A, Day SE, Chusid MJ, Peterson DE, Markowitz LE, and

- Davis JP. Measles severity and serum vitamin A levels. Presented at 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 29 September - 2 October, 1991, Chicago, IL.
22. *Gedeit R, Weigle C, Werlin S, and **HAVENS P**. Ranitidine and control of gastric pH in critically ill children. Presented at the 5th Pediatric Critical Care Colloquium, Snowbird, Utah, January 26-30, 1992.
 23. Bresnahan J, Babel K, Splaingard M, and **HAVENS PL**. Survival and functional outcome of children requiring assisted ventilation during therapy for acute bacterial meningitis. Presented at the 5th Pediatric Critical Care Colloquium, Snowbird, Utah, January 26-30, 1992.
 24. Kelly KJ, Kurup VP, Resnick A, Fink JN, Roberts M, Grammer L, and **HAVENS PL**. A case control study of hypersensitivity to latex, ethylene oxide, and allergic factors predicting anaphylaxis in pediatric patients undergoing general anesthesia. Presented at the American Academy of Allergy and Immunology Annual Meeting, Orlando, Florida, March 8, 1992.
 25. *McAuliffe J, Wendelberger KJ, **HAVENS PL**. Predicting need for resuscitation in hospitalized pediatric patients. Presented at the American Academy of Pediatrics Fall Meetings, Section on Critical Care, San Francisco, CA, October 10-15, 1992.
 26. *Torres A, Hoffman GM, Werlin SL, Walker L, Cochran J, Reddy MN, **HAVENS PL**. Persistent catabolism despite increased anabolic hormone production in critically ill children. Presented at the Pediatric Critical Care Colloquium, Philadelphia, PA, March 28-31, 1993.
 27. Hoffman GM, Torres A, **HAVENS PL**, Walker L, Reddy MN, Werlin SL. High RQ does not indicate anabolic state in critically ill patients. Presented at the Pediatric Critical Care Colloquium, Philadelphia, PA, March 28-31, 1993. Published in *Anesthesiology* 1993;79(3A):A264.
 28. *Thakker J, Kim J, Splaingard M, Babel K, Bresnahan J, **HAVENS PL**. Survival and functional outcome in children with severe traumatic brain injury. Presented at the Pediatric Critical Care Colloquium, Philadelphia, PA, March 28-31, 1993.
 29. *Sachdeva RC, Torres A, Person AD, Oddo CT, Sabnis SS, Montano ST, Rimm AA, **HAVENS PL**. Early predictors of prolonged PICU stay. Presented at the Pediatric Critical Care Colloquium, Philadelphia, PA, March 28-31, 1993.
 30. *Cochran J, Palmisano B, **HAVENS PL**, Weigle C. Comparison of heart rate variability in healthy pre-operative patients and patients in PICU. Presented at the Pediatric Critical Care Colloquium, Philadelphia, PA, March 28-31, 1993.
 31. Yabut B, Werlin S, **HAVENS P**, Bohorfoush. The role of ERCP in Pediatric AIDS. Submitted to the North American Society for Pediatric Gastroenterology and Nutrition Meeting, Houston, TX, Oct 10-12, 1994.
 32. Kehl KS, **HAVENS P**, Chusid MJ. Sensitivity of BacTec blood culture method for the

- detection of positives at two days. Presented at the 94th General Meeting of the American Society for Microbiology. Las Vegas, Nevada. May 23-27, 1994.
33. Kehl KS, Cicirello H, **HAVENS P**. Comparison of methods for the detection of cryptosporidium in children. Presented at the 94th General Meeting of the American Society for Microbiology. Las Vegas, Nevada. May 23-27, 1994.
 34. Cuene BE, **HAVENS PL**, Kovnar SG, Marquardt KM. Wisconsin HIV Primary Care Support Network. Presentation at the Seventh Annual Conference of the Association of Nurses in AIDS Care, November 10-12, 1994. Nashville, TN.
 35. *Spack L, Griffith O, **HAVENS PL**, Narayanan K. Effects of nitric oxide synthase inhibitors on blood pressure in rats. Presented at the Pediatric Critical Care Colloquium, Seattle, WA, October 26-29, 1994.
 36. *Spack L, Gedeit R, **HAVENS P**, Splaingard M. Failure of aggressive therapy to alter outcome in pediatric near drowning. Presented at the Pediatric Critical Care Colloquium, Seattle, WA, October 26-29, 1994.
 37. **HAVENS PL**, Waters D, Hand J. Children's Hospital of Wisconsin Pediatric and Adolescent HIV Care Program. Presented at National Association of Children's Hospitals and Related Institutions (NACHRI) Annual Meeting, October 5-7, 1994. Salt Lake City, UT.
 38. **HAVENS PL**, Cuene BE, Waters D, Marquardt KM, Hand JR, Chusid MJ. Effectiveness of a primary provider-based program for care of children with HIV infection. Presented at the Second National Conference on Human Retroviruses and Related Infections, Washington, DC. Jan 29 - Feb 2, 1995.
 39. Kehl KS, Behnke C, **HAVENS P**. Development of cost effective enteric pathogen testing based on surveillance, patient location, and season. Presented at the American Society of Microbiology Annual Meeting, Washington, D.C. May 21-25, 1995.
 40. Kehl KS, Proctor M, Mellen J, **HAVENS P**. Culture for E. coli O157:H7 and testing for Shiga-like toxin during an outbreak of diarrhea in a daycare center. Presented at the American Society of Microbiology Annual Meeting, Washington, D.C. May 21-25, 1995.
 41. *Ross GA, Hoffman GM, Wendelberger KJ, Nelin LD, Day SE, Weigle CGM, Rice TB, **HAVENS PL**. Availability of nitric oxide inhalation therapy reduces use of extracorporeal membrane oxygenation (ECMO) as therapy for severe neonatal respiratory failure. Presented at the Pediatric Critical Care Colloquium, October 2-4, 1995, South Carolina.
 42. *Spack LC, Griffith O, **HAVENS PL**, Brazovich L. Serum nitrite/nitrate concentrations in pediatric patients with the systemic inflammatory response syndrome (SIRS). Presented at the Pediatric Critical Care Colloquium, October 2-4, 1995, South Carolina.
 43. **HAVENS PL**, Cuene BE, Hand JR. Lifetime cost of care for children with HIV infection. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Jan 28-Feb 1, 1996, Washington, DC.

44. Cuene BE, **HAVENS PL**, Hanlon-Lundberg K, Hand JR, Reiser W, Vergeront J. Universal HIV Counseling and Voluntary Testing for pregnant women: an educational strategy for implementation in a low HIV prevalence, rural state. Presented at the Ninth Annual Association of Nurses in AIDS Care Conference, Oct 31-Nov 3, 1996, Chicago, IL.
45. *Balasubramanyan N, **HAVENS PL**, Hoffman GM. Fencl-Stewart acid-base method compared with base excess/anion gap method in PICU patients. Presented at American Society of Anesthesiologists Annual Meeting, Oct 1996, New Orleans, LA.
46. **HAVENS PL**, Cuene BE. Effectiveness of Perinatally Administered Zidovudine (ZDV) in Decreasing Vertical Transmission of HIV Infection in Wisconsin. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Jan 22-26, 1997, Washington, DC.
47. **HAVENS PL**, Cuene BE. Impact of an Educational Program to Change Provider Practice Concerning HIV Counseling and Testing of Pregnant Women. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Jan 22-26, 1997, Washington, DC.
48. *Balasubramanyan N, **HAVENS PL**, Hoffman GM. Fencl-Stewart Acid-Base Method Predicts Lactic Acidosis Better than Standard Methods in Pediatric Intensive Care Unit Patients. Presented at the 26th Educational and Scientific Symposium, Society of Critical Care Medicine, Feb 6-10, 1997, San Diego, CA.
49. **HAVENS PL**, Cuene BE, for the HIV Research Consortium for Children, Youth, Women, and Families. Effects of Parent and Provider Attitude on Frequency of Use of Protease Inhibitors in Children and Adolescents with HIV Infection. Presented at the Ryan White Title IV Demonstration Projects Annual Meeting, Washington, D.C., Nov 17-18, 1997.
50. **HAVENS PL**, Cuene BE, for the HIV Research Consortium for Children, Youth, Women, and Families. Safety and Efficacy of Protease Inhibitor Therapy in Children and Adolescents with HIV Infection. Presented at the Ryan White Title IV Demonstration Projects Annual Meeting, Washington, D.C., Nov 17-18, 1997.
51. **Havens PL**, Cuene BE, for the HIV Research Consortium for Children, Youth, Women, and Families. Efficacy of Protease Inhibitor Therapy in Children and Adolescents with HIV Infection. Presented at 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sept 24-27, 1998, San Diego, CA.
52. *Beckmann KR, **HAVENS PL**, Cuene BE, Dietz M, Melzer-Lange M. The Effectiveness of a call-back program at increasing human immunodeficiency virus (HIV) testing in a pediatric emergency department. Presented at the Ambulatory Pediatric Association Annual Meeting, 1999.
53. Bower DJ, **HAVENS PL**, Derse AR, Autry AM. Ethical Dilemmas: Pregnancy Care for an HIV-positive woman who refuses Treatment for herself and her newborn. Medical College of Wisconsin Department of Family and Community Medicine 8th Research Forum, June 7, 1999. Milwaukee, WI.

54. *Meyer MT, Berens RJ, **HAVENS PL**. Association of the Nursing Assessment of Withdrawal with the Neonatal Abstinence Score. Presented at the Pediatric Critical Care Colloquium, Sept. 22-26, 1999, Portland. OR. Published in Clin Intensive Care 1999;10:151.
55. *Meyer MT, Berens RJ, **HAVENS PL**. Association of the Nursing Assessment of Withdrawal with the Neonatal Abstinence Score. Presented at the Society of Critical Care Medicine Annual Meeting, Feb 11-15, 2000, Orlando, FL.
56. Peter LD, Hancock B, Ivantec-Doucette K, Barabe D, **HAVENS PL**. Outcome evaluation of a Title 4 Women's Support Program. Ryan White Care Act Grantee Conference, Washington, DC. Aug 30-23, 2002.
57. *Skoumal KS, Splaingard ML, Crowe MJ, Gennarelli TA, **HAVENS PL**. Apolipoprotein E epsilon 4 in pediatric traumatic brain injury: Phase I-Difficulty in obtaining approvals and patient enrollment. Presented at the First Joint Symposium of the National and International Neurotrauma Societies, November, 2002.
58. *Rao AR, Splaingard MS, Gershan WM, **HAVENS PL**, Barbieri JT. Pseudomonas Type-III antibody detection in children with tracheostomies. Presented at the American Thoracic Society 100th International Conference, May 21 to 26, 2004, Orlando, FL
59. **HAVENS P**, Frank M, Cuene B, Decker V, Kohler R, Wolfe A, Yenter M. Pharmacokinetics and safety of lopinavir/ritonavir doses greater than 300 mg/m²/dose in children and adolescents with HIV infection. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, Feb 8-11, 2004, San Francisco, CA.
60. *Lee KJ, **HAVENS PL**, Hoffman GM, Sato TT, Leuthner SR. Pediatric Assent - Clinician Knowledge, Attitudes, and practice. Pediatric Academic Societies Annual Meeting, May 1-4, 2004, San Francisco, CA
61. *Tieves KS, Musynski CA, Kaufman, BA, Havens PL. Changes in the outcome of pediatric patients with severe traumatic brain injury over time. Pediatric Critical Care Colloquium Sept. 30-Oct 2, 2004, New York, New York; Society of Critical Care Medicine Symposium Jan 15-19, 2005.
62. *Tieves KS, Scanlon MC, Rice TB, **HAVENS PL**. Outcome of pediatric patients with head injury: Center differences in mortality and functional outcome at PICU discharge. Pediatric Critical Care Colloquium Sept. 30-Oct 2, 2004, New York, New York.
63. *Tieves KS, Muszynski CA, Kaufman BA, **HAVENS PL**, Thakker JC. Changes in the outcome of pediatric patients with severe traumatic brain injury over time. Crit Care Med Vol. 32, No. 12 (Supp): A101 Presented at SCCM 34th Critical Care Congress Jan. 15-19, 2005. Phoenix, AZ
64. Punzalan R, *Hanson S, Ghanayem N, **HAVENS PL**. The prevalence of heparin dependent antibodies in children after cardiopulmonary bypass. Presented at the American Society of Hematology Meeting, December, 2005.

65. *Hanson S, Ghanayem N, Punzalan R, **HAVENS PL**. The prevalence of heparin dependent antibodies in children after cardiopulmonary bypass. Presented at the AATS meeting, Spring, 2006.
66. *Skelton JA, Mullin S, Otto M, Mao J, **HAVENS PL**. Body mass index distribution in a tertiary care constipation clinic. Presented at NASPGHAN 2005 annual meeting.
67. Persaud D, **HAVENS PL**, Palumbo R, Chadwick E. Acquisition and archiving of non-nucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 variants during mother to child transmission in U.S. born infants. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Feb 5-9, 2006, Denver, CO
68. O'Connor KG, Havens PL, Henry-Reid L, Lindros J, Klein JD, Futterman D. Discussing high-risk behaviors with adolescents: Results of a national survey of pediatricians. Accepted to the American Public Health Association Meeting, November, 2006.
69. Stolzman SC, *Skelton JA, Irwin N, Hackbarth H, Mao J, **HAVENS PL**. Musculoskeletal and exercise limitations in an overweight population. Presented at the Pediatric Academic Societies Meeting, May, 2006.
70. **Robbins B, **HAVENS PL**, Capparelli E, Chadwick E, Yogev R, Serchuck L, Aldronvandi G, Alvero C, Heckman B, Rodman J and PACTG 1038 Team. Pharmacokinetics (PK) of high-dose lopinavir (LPV)/ritonavir ® with and without saquinavir (SQV) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) in HIV infected pediatric and adolescent patients previously treated with protease inhibitors (PI). Submitted to the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, 2007.
71. **Kiser JJ, Fletcher CV, Flynn P, Cunningham CK, Wilson CM, Kapogiannis B, Major-Wilson H, Viani RM, Muenz L, Harris DR, **HAVENS PL**, and the Adolescent Trials Network for HIV/AIDS Intervention. Pharmacokinetics of antiretroviral regimens containing Tenofovir Disoproxil Fumarate (TDF) and Atazanavir/Ritonavir (ATV/RTV) in adolescents and young adults with HIV infection – Study ATN056. 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, April 16-18, 2007, abstract 12
72. Franklin JA, Lim HJ, **HAVENS PL**. Longitudinal academic and social progress of children with perinatally acquired HIV. Presented at the Annual Convention of the American Psychological Association, San Francisco, CA, Aug 18, 2007
73. *Hanson SJ, Punzalan R, Greenup R, Lui H, Sato TT, **HAVENS PL**, "Risk Factors for Venous Thromboembolism in Critically Ill Children after Trauma". Presented at 17th Pediatric Critical Care Colloquium, February 2008, Whistler, Canada.
74. *Hanson SJ, **HAVENS PL**, Wells R, "Comparison of Intrapleural Alteplase Fibrinolysis vs. Normal Saline Irrigation on Parapneumonic Effusion Drainage Volume in Children." Accepted for poster presentation at American Thoracic Society, May 2008, Toronto, Canada.
75. Mulligan K, **HAVENS P**, and the ATN 063 Team. Evidence of Renal Tubular Impairment and Increased Bone Turnover in HIV-infected Adolescents and Young Adults on Tenofovir-

- containing cART: Baseline Results of the Adolescent Trials Network (ATN) Study 063. Oral presentation at the 12th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV, November 4-6, 2010, London, UK.
76. Havens P. L., Hazra R, Stephensen CB, van Loan M, Rutledge B, Bethel J, Pan C, Liu N., Lujan-Zilberman J, Mulligan K. (2011). Vitamin D3 (VITD) Supplementation Decreases Parathyroid Hormone (PTH) in HIV-infected Youth Being Treated with Tenofovir (TDF)-containing Combination Antiretroviral Therapy (cART): a Randomized, Double-blind, Placebo-controlled Multicenter Trial (RCT): Adolescent Trials Network (ATN) study 063. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA.
 77. Baheti G, Brundage RC, Kiser JJ, **HAVENS P**, Fletcher CV, and the Adolescent Trials Network for HIV/AIDS Interventions. Plasma and Intracellular Population Pharmacokinetics Analysis of Tenofovir in HIV-1 Infected Patients. Poster presentation to the 2011 American Conference on Pharmacometrics (ACoP), April 3-6, 2011, San Diego, CA
 78. **Havens PL**, Mulligan K, Hazra R, Van Loan MD, Pan CG, Bethel J, Rutledge BN, Kapogiannis BG, Flynn PM, Lujan-Zilberman J, Kiser JJ, Baker AM, Liu NX, Worrell C, Wilson CM, Stephensen CB for the ATN 063 protocol team. Safety and efficacy of once-monthly dosing of vitamin D3 (50,000 IU) in HIV-infected youth: Adolescent Trials Network Study 063. Presented at the 13th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. Rome, Italy, July 2011. *Antiviral Therapy* 2011; 16 (suppl2): A9
 79. **HAVENS PL**, Mulligan K, Hazra R, Van Loan MD, Rutledge BN, Bethel J, Pan CG, Flynn PM, Lujan-Zilberman J, Gordon, CM, Woodhouse, LR, Kiser JJ, Meyer III, WA, Baker AM, Liu NX, Wilson CM, Stephensen CB for the ATN 063 protocol team. Increase in fibroblast growth factor 23 in response to vitamin D3 supplementation in HIV-infected adolescents and young adults on tenofovir-containing combination antiretroviral therapy: Adolescent Trials Network (ATN) study 063. 14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, Washington, DC, July 19-21, 2012. *Antiviral Therapy* 2012; 17 Suppl 2: A7
 80. Getting to Zero and the Efforts To Stay There: Coordinated Care for the Prevention of Perinatal HIV Infection in Wisconsin. Decker, V., Meyer, T., Gidan, S., Hand, J., Kohler, R., Ntambi, S., Simonich, W., Cuene, B., Henderson, S. and **HAVENS P**. Wisconsin Association for Perinatal Care. April 2014
 81. Mulligan K, Rutledge B, Kapogiannis B, Siberry G, Anderson, Landovitz R, Rudy B, Liu N, Rooney J, **HAVENS P**, Wilson CM, Hosek S, ATN 110 protocol team and the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Bone Changes in Young Men Ages 18-22 Enrolled in a Pre-Exposure Prophylaxis (PrEP) Demonstration Project Using Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC). Oral presentation at the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, Barcelona, Spain, October 21-24, 2015.
 82. Mulligan K, Hosek S, Kapogiannis BG, Landovitz RJ, Liu N, Cofield SS, Perumean-Chaney SE, Rutledge B, **HAVENS PL**, Wilson CM, and the Adolescent Medicine Trials Network

for HIV/AIDS Interventions. Changes in Bone Mass after Discontinuation of PrEP with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Young Men Who Have Sex with Men (YMSM): Extension Phase Results of Adolescent Trials Network (ATN) 110. Submitted as a late-breaker abstract to the 21st International AIDS Society Conference, Durban, South Africa, July 18-22, 2016.

83. **HAVENS P**, Stephensen C, Van Loan M, Rutledge B, Harris B, Flynn P, Gordon C, Kapogiannis B, Mulligan K, and Adolescent Trials Network (ATN) Study 109 Team. (TDF)High dose vitamin D3 increases spine bone density in HIV+ youth on Tenofovir (TDF). Abstract 685LB. Presented at the Conference on Retroviruses and Opportunistic Infections, Feb 13-16, 2017, Seattle, WA.

* The first authors of these publications were trainees supervised by Dr. Havens at the time the investigations were performed.

** Dr. Havens is Principal Investigator/Protocol Chair